[Off-label therapies in oncology].
The unapproved (off-label) therapies represent a special problem in oncology since they are in the borderline of legal regulation and of free medical practice. Although in Hungary the off-label therapies were regarded as clinical trials without permission until the new regulation came into action at the end of October 2008, certain experts were even so arguing for its use because clinical practice changes more rapidly than the prescription label. Moreover, manufacturers are not obliged to submit Supplemental New Drug Application in spite of the fact that enough evidence is generated to do so. The regulation of off-label therapies should meet the conditions of free medical practice, evidence-based medicine, demand of patients for new chances and expectations of regulatory authorities. In this paper, following the criticism of the Hungarian status and the new regulation, as well as the review of international practice, the author outlines the frame of a potential regulation separately indicating the role of practicing physicians and authorities.
Telekes
András
A
Országos Onkológiai Intézet (2009. január 1-jétol: Bajcsy-Zsilinszky Kórház és Rendelointézet) III. Belgyógyászati Ambulancia (2009. január 1-jétol: Onkológiai Osztály) 1106 Budapest Maglódi u. 89-91, Hungary. andras.telekes@bajcsy.hu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D006814:Hungary; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010818:Practice Patterns, Physicians' / Q000639:trends*
D000970:Antineoplastic Agents